Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Myeloma-Multiple”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT02033928
What this trial is testing

Comprehensive Frailty Assessment

Who this might be right for
Myeloma, MultipleParaproteinemiasHematologic Neoplasms
Ohio State University Comprehensive Cancer Center 111
Testing effectiveness (Phase 2)Study completedNCT03773107
What this trial is testing

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Wake Forest University Health Sciences 12
Testing effectiveness (Phase 2)Study completedNCT01720875
What this trial is testing

Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)

Who this might be right for
Multiple Myeloma
University of Leeds 16
Not applicableLooking for participantsNCT05259553
What this trial is testing

Biomarkers in Multiple Myeloma

Who this might be right for
Hematological PatientsNewly Diagnosed Multiple MyelomaChemotherapy
Centre Hospitalier Universitaire de Saint Etienne 70
Testing effectiveness (Phase 2)Ended earlyNCT02294357
What this trial is testing

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Who this might be right for
Multiple Myeloma
Oncotherapeutics 45
Large-scale testing (Phase 3)Active Not RecruitingNCT04071457
What this trial is testing

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Who this might be right for
Multiple Myeloma
SWOG Cancer Research Network 1,100
Early research (Phase 1)UnknownNCT04984434
What this trial is testing

Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD 68
Not applicableStudy completedNCT06610045
What this trial is testing

The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study

Who this might be right for
Multiple MyelomaCaregiver Subjective BurdenQuality of Life (QOL)
PeriPharm 400
Large-scale testing (Phase 3)UnknownNCT02270307
What this trial is testing

MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis

Who this might be right for
LeukemiaMultiple Myeloma
National Research Center for Hematology, Russia 40
Early research (Phase 1)Study completedNCT03111992
What this trial is testing

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals 26
Very early researchStudy completedNCT02117115
What this trial is testing

Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic+1 more
Washington University School of Medicine 21
Not applicableStudy completedNCT04045561
What this trial is testing

Development of a Standardized Reference Guide for Tuning Adherence to Dispense During a Initial Pharmaceutical Consulting (CP ) to the Patient With Multiple Myeloma Oral Chemotherapy Primocure

Who this might be right for
Multiple Myeloma
Centre Hospitalier Universitaire de Nīmes 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04998786
What this trial is testing

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

Who this might be right for
Multiple Myeloma at First Relapse
Nantes University Hospital 75
Testing effectiveness (Phase 2)Looking for participantsNCT06627751
What this trial is testing

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Who this might be right for
Extramedullary Disease in Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Roswell Park Cancer Institute 28
Post-approval studies (Phase 4)Study completedNCT05555329
What this trial is testing

Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study

Who this might be right for
Multiple Myeloma in RelapseMultiple MyelomaMultiple Myeloma, Refractory
Amsterdam UMC, location VUmc 12
Not applicableStudy completedNCT03046329
What this trial is testing

Improving the Quality of Multiple Myeloma Treatment With Patient Care Plans

Who this might be right for
Multiple Myeloma
Carevive Systems, Inc. 90
Testing effectiveness (Phase 2)Study completedNCT00800839
What this trial is testing

Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide

Who this might be right for
Hematologic DiseasesLeukemiaLymphoma+1 more
M.D. Anderson Cancer Center 56
Testing effectiveness (Phase 2)Looking for participantsNCT06100237
What this trial is testing

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

Who this might be right for
Multiple Myeloma
Carl Ola Landgren, MD, PhD 50
Early research (Phase 1)Study completedNCT03263637
What this trial is testing

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Who this might be right for
Relapsed or Refractory Haematological Malignancies IncludingAcute Myeloid LeukemiaAcute Lymphocytic Leukemia+8 more
AstraZeneca 44
Testing effectiveness (Phase 2)Study completedNCT00064311
What this trial is testing

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more
National Institutes of Health Clinical Center (CC)
Next Page